Monitoring treatment response with urine and serum metabolome markers
Research type
Research Study
Full title
Monitoring treatment response with urine and serum metabolome markers in patients treated with novel hormone therapy and have either hormone sensitive metastatic prostate cancer or disease progression on treatment
IRAS ID
358728
Contact name
Isabel Syndikus
Contact email
Sponsor organisation
The Clatterbridge Cancer Centre NHS Foundation Trust
Duration of Study in the UK
4 years, 2 months, 3 days
Research summary
80% of patients with newly diagnosed metastatic hormone sensitive prostate cancer have bone metastases. There are mutations that are described with early disease progression when on hormone therapy for prostate cancer. In the NHS setting it is difficult to detect and monitor the patients. There are biochemical changes in the body that are associated with bone metastasis which can be detected in bodily fluids such as urine. Metabolites are substances involved in metabolism (= the chemical processes in the body needed for life. They are usually small molecules. Metabolomics is a way of studying the 'metabolome' which is the entire complement of small molecules present within the body. The metabolites are very sensitve to environmental or other changes and these can be markers for change caused by prostate cancer metastasis. Therefore the urinary metabolome is is potentially a very good indicator of change caused by cancer and hormone treatment. Accurate and specific urine tests would be a way to allow better monitoring of patients. This study aims to investigate the changes of specific bone urinary metabolome markers (UMMs) and untargeted urine profiles to detect the response and progression of patients with prostate cancer (PC). We propose that UMMs are simpler, less difficult for patients and more sensitive and specific compared to conventional imaging and routine blood tests, the current gold standard.
REC name
London - Hampstead Research Ethics Committee
REC reference
25/LO/0670
Date of REC Opinion
9 Dec 2025
REC opinion
Further Information Favourable Opinion